Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To evaluate the role of IgM specific antibody in the diagnosis and monitoring of the patients with chronic hepatitis C, sera from 114 cases with chronic hepatitis C and liver cirrhosis were tested. IgM antibody to hepatitis C virus was detected in 40.0% of CAH, as compared with 21.4% of CIH, 17.4% of LC, 20.0% of LC with HCC. IgM antibody was also detectable in cases with high level of s-ALT. Patients with positive this antibody have high titer of IgG antibody to hepatitis C virus. In summary, testing for this antibody may be useful to evaluate the recurrence or disease activity and may also be helpful in IFN therapy.
 ...
PMID:[IgM HCV antibody in chronic hepatitis and liver cirrhosis]. 138 May 70

Alpha-fetoprotein (AFP) levels were studied in 51 consecutive patients with hepatocellular carcinoma that presented to the Surgical Hepatobiliary Unit at Westmead Hospital over 12 years. Twenty-three were hepatitis surface antigen (HBsAg) positive and 13 of those patients were Asian. Thirteen patients drank more than 60 g of alcohol each day. A significantly raised level of AFP was defined as more than 20 ng/mL, and 31 of the 51 patients had AFP levels exceeding this at some stage during surveillance. Twenty-five demonstrated levels above 200 ng/mL. Univariate statistical methods suggested that men were more likely to express raised AFP than women, Asians more likely than other races, patients with chronic active hepatitis more likely than those without and those with chronic hepatitis B infection more likely than those who were HBsAg negative. Those who drank more than 60 g alcohol each day were less likely to demonstrate a raised serum AFP than those who drank less. Multivariate logistic regression demonstrated that HBsAg carriage was the only statistically significant independent determinant of a raised AFP. Age 65 years or more was associated with a chance of a raised AFP.
 ...
PMID:Alpha-fetoprotein expression in hepatocellular carcinoma: a clinical study. 138 Dec 28

Epidemiological data disclose that the incidence of hepatocellular carcinoma (HCC) is increasing world-wide, whereas the number of cases positive for HBV-marker has remained almost stable, at least in Japan. Data from Europe show positivity of antibodies against hepatitis C virus (anti-HCV) in 72% of HBsAg negative cases with HCC and in 28% of patients positive for HBsAg. Nearly 90% of HBsAg negative patients with HCC showed a histology of cirrhosis or chronic active hepatitis in the noncancerous liver. Almost every third patient had a history of blood transfusion. These results suggest an increasing incidence of HCV - associated HCC's, as it already has been shown for patients suffering from chronic HBV infection.
 ...
PMID:[Hepatitis C infection and liver cell carcinoma]. 138 6

To find out the prevalence of antibody of hepatitis C virus (anti-HCV) in patients with chronic liver disease in Bombay, sera from 126 patients (93 men, 33 women; aged 9-70 years, mean 39.7) with chronic liver disease (cirrhosis 103, cirrhosis with hepatocellular carcinoma 3, chronic active hepatitis 20) were tested for HBsAg and anti-HCV antibody. HBsAg positive sera were tested for anti-delta antibody and IgM anti-HBc. All the tests were carried out by ELISA. Of 126 patients, 51 (40.5%) were HBsAg positive, 49 (38.8%) alcoholic and 21 (16.6%) anti-HCV positive. The prevalence of anti-HCV in HBsAg positive, alcoholic and cryptogenic (HBV negative and no alcohol) liver disease patients was 13.7%, 14.7% and 20.5% respectively. Of 21 anti-HCV antibody positive patients, 8 (38%) had received blood transfusions previously. HCV is present in 15-20% of patients with chronic liver disease in Bombay.
 ...
PMID:Hepatitis C virus infection in chronic liver disease in Bombay. 138 41

The prevalence of antibodies against hepatitis C virus (anti-HCV) was determined in 55 patients with chronic liver diseases including liver cirrhosis (42 patients), liver cirrhosis and hepatocellular carcinoma (8 patients), and chronic active hepatitis (4 patients). A total of 63.6% of these patients were positive for anti-HCV, a significantly higher prevalence than the rate of 3.9% observed in 488 asymptomatic volunteers. Of the 42 patients with liver cirrhosis 16 (38.1%) had positive anti-HCV without any markers of hepatitis B virus (HBV), while 12 (28.6%) had markers of neither HCV nor HBV infection. Our findings suggest that HCV infection may play a significant role in the pathogenesis of chronic liver disease in Saudi Arabia, which is an area of endemic HBV infection. Screening for anti HCV should be considered mandatory in patients with chronic liver disease (CLD) especially where the etiology appears obscure.
 ...
PMID:Prevalence of antibodies to hepatitis C virus among Saudi patients with chronic liver diseases. 138 86

1 141 serum samples from various population groups in north China were examined for C100-3Ab by ELISA. Antibody to C100-3 antigen derived from HCV genome (C100-3A) and HBsAg were measured in 438 normal population in Beijing. The C100-3Ab positive rate was 2.1% and the HBsAg positive rate was 2.5%. There is increased occurrence with age. In 649 cases of chronic liver diseases, the HBsAg positive rate was 87.1% in chronic persistent hepatitis (CPA), 88.8% in chronic active hepatitis (CAH), 64.9% in liver cirrhosis (LC) and 67.3% in hepatocellular carcinoma (HCC). The C100-3Ab positive rate was 10.5% (CPH), 12.1% (CAH), 42.6% (LC) and 38.4% (HCC). It is noteworthy that the C100-3Ab positive rate significantly increased with disease progression from CPH to CAH, LC and HCC. Prevalence of cases positive for both C100-3Ab and HBsAg was 0% in the normal population, 6.7% in CPH, 8.4% in CAH, 31.1% in LC and 28.8% in HCC. Investigation of patients with HCV infection showed that only 36.8% had blood transfusions. HCV and HBV infection may play important pathogenic roles in CPH, CAH, LC and HCC in north China.
 ...
PMID:Preliminary report on seroepidemiology of HCV and HBV infection in northern China. 139 40

The hepadnavirus family contains a number of related viruses able to infect a variety of animal species. In the present study, we have used the polymerase chain reaction and oligonucleotide primers to a conserved region of the viral replicase gene of hepadnaviruses to identify viral sequences in de novo tissues in three well-characterized hepadnavirus systems: the woodchuck, ground squirrel and Pekin duck. We did not detect related hepadnavirus sequences in liver specimens from tree squirrels putatively infected with the tree squirrel hepatitis virus, or in liver specimens from horses with hepatitis (serum sickness), or from dogs with chronic active hepatitis or hepatocellular carcinoma.
 ...
PMID:Detection of mammalian and avian hepadnaviruses by the polymerase chain reaction. 145 24

An enzyme-linked immunosorbent assay (ELISA) was developed for human beta-glucuronidase, using a specific polyclonal antibody raised against the purified enzyme. beta-Glucuronidase from human liver consisted of three subunits with molecular mass of 76, 64 and 18 kDa. The assay offered a specific, sensitive and convenient means of measuring immunoreactive beta-glucuronidase in human sera. beta-Glucuronidase activity determined by the conventional method appeared to be extremely low, indicating that in human sera beta-glucuronidase exists in an enzymatically inactive form. The sensitivity of the assay permitted the detection of 1-100 ng of purified beta-glucuronidase. A mean serum level in normal subjects was 108 +/- 25 ng/ml (mean +/- S.D.). A high level of beta-glucuronidase was found in sera of patients with severe hepatocellular necrosis, including liver cirrhosis (152 +/- 130 ng/ml) and chronic active hepatitis (220 +/- 99 ng/ml), whereas no significant increase of the enzyme protein was observed in chronic persistent hepatitis (102 +/- 42 ng/ml). beta-Glucuronidase was also increased in sera of patients with primary hepatoma (156 +/- 125 ng/ml). The immunoreactive beta-glucuronidase determined in this assay was thought to be a supplementary serological indicator for hepatocellular necrosis.
 ...
PMID:Serum immunoreactive beta-glucuronidase determined by an enzyme-linked immunosorbent assay in patients with hepatic diseases. 163 57

In a rapid 51Cr release assay, peripheral blood mononuclear cells from 12 healthy donors did not lyse the hepatitis B virus deoxyribonucleic-acid-transfected human hepatoma cell line 2.2.15, but under the same experimental conditions they did lyse K562 cells. Peripheral blood mononuclear cells from 10 out of 16 patients with chronic active hepatitis B exhibited cytotoxic activity against 2.2.15 cells in the presence of a relatively reduced natural killer cell activity to the K562 cell target. Enhancement of the cytotoxic activity to 2.2.15 cells was statistically significant in the group of patients being treated with leukocyte alpha-interferon. The activity was not influenced by the degree of human leukocyte antigen type matching between effector and target, and was enhanced by depletion of T-cells and by in vitro interferon treatment. These results therefore support the concept of a natural killer-like cell activated by clinical administration of interferon in chronic active hepatitis B patients. This cell effector was lytic for the virus B negative HEP-G2 cells also. However, T-cells purified from a few patients failed to lyse the HEP-G2 while lysing the 2.2.15 target, thus indicating that a preferential recognition of the virus-infected target may be exerted by certain T-lymphocyte subsets. The use of the human leukocyte antigen type defined, highly differentiated, hepatitis B virus releasing 2.2.15 cell line as target for fresh lymphocytes in this cytolytic assay did not disclose cytolytic T-cells in an obvious way. Further manipulation of this system perhaps using T-cell clones may be the next step to exploit the investigative possibilities offered by the availability of the 2.2.15 cell target.
 ...
PMID:Chronic active hepatitis B. Interferon-activated natural killer-like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. 164 27

A serum analysis for antibodies to the hepatitis C virus (HCV) was performed on a group of patients in a large suburban Detroit community hospital. The first 50 anti-HCV-positive patients with clinically suspected chronic non-A, non-B hepatitis were studied. Blood transfusions (58%) and intravenous drug use (22%) were the source of infection in most of these patients. A significant difference in age-related epidemiology was observed (p = 0.001). A remote history of intravenous drug use or tattoo application was elicited in 55% of individuals less than 40 yr old. "Sporadic" transmission occurred in 28% of individuals older than 50 yr. Sixteen percent (8/50) had no identifiable risk factors. Five of these eight patients (63%) were born and raised outside North America. Eighty percent of the 35 persons who underwent liver biopsy were found to have either chronic active hepatitis or cirrhosis. Twenty-nine percent (5/17) of the patients with anti-HCV-related cirrhosis presented with hepatocellular carcinoma. None of the patients with noncirrhotic liver disease had a primary liver tumor. We conclude that a significant number of patients in suburban America with chronic hepatitis C have no identifiable risk factors for HCV. Sporadic transmission of hepatitis C may play an important role in patients with chronic HCV-related liver disease, especially among patients born and raised outside North America.
 ...
PMID:Epidemiology of hepatitis C virus infection in a suburban Detroit community. 165 86


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>